Cognitive impairment and C-reactive protein in clinically stable schizophrenia outpatients: a focus on sex differences

[1]  M. Leboyer,et al.  Relationship between neurocognition and theory of mind as a function of symptomatic profile in schizophrenia: results from the national FACE-SZ cohort , 2021, Cognitive neuropsychiatry.

[2]  Y. Imanaka,et al.  Factors associated with high‐dose antipsychotic prescriptions in outpatients with schizophrenia: An analysis of claims data from a Japanese prefecture , 2020, Neuropsychopharmacology reports.

[3]  J. Bobes,et al.  Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition: A mediation model , 2020, European Neuropsychopharmacology.

[4]  L. Goh,et al.  Mindfulness improves inflammatory biomarker levels in older adults with mild cognitive impairment: a randomized controlled trial , 2020, Translational Psychiatry.

[5]  K. Burdick,et al.  C-reactive protein is associated with cognitive performance in a large cohort of euthymic patients with bipolar disorder , 2019, Molecular Psychiatry.

[6]  K. Nuechterlein,et al.  Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations
 , 2019, Dialogues in clinical neuroscience.

[7]  V. Steen,et al.  Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis , 2018, Acta Neuropsychiatrica.

[8]  G. Fond,et al.  C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review , 2018, Front. Psychiatry.

[9]  N. Müller.  Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations , 2018, Schizophrenia bulletin.

[10]  L. D. L. Fuente-Tomás,et al.  Elevated C-reactive protein as a predictor of a random one-year clinical course in the first ten years of schizophrenia , 2018, Psychiatry Research.

[11]  D. Goldsmith,et al.  What does plasma CRP tell us about peripheral and central inflammation in depression? , 2018, Molecular Psychiatry.

[12]  B. Arranz,et al.  Gender differences in C-reactive protein and homocysteine modulation of cognitive performance and real-world functioning in bipolar disorder. , 2018, Journal of affective disorders.

[13]  E. Choleris,et al.  Sex differences in the brain: Implications for behavioral and biomedical research , 2018, Neuroscience & Biobehavioral Reviews.

[14]  J. Bobes,et al.  Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis? , 2018, Psychological Medicine.

[15]  N. Neznanov,et al.  Cognitive deficit in patients with paranoid schizophrenia: Its clinical and laboratory correlates , 2017, Psychiatry Research.

[16]  J. Rybakowski,et al.  Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review , 2017, Schizophrenia Research.

[17]  Kristen N. Krolick,et al.  Effects of Estrogens on Central Nervous System Neurotransmission: Implications for Sex Differences in Mental Disorders. , 2018, Progress in molecular biology and translational science.

[18]  M. Leboyer,et al.  Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort , 2018, European Archives of Psychiatry and Clinical Neuroscience.

[19]  Alexander J. Riordan,et al.  Estrogens and the cognitive symptoms of schizophrenia: Possible neuroprotective mechanisms , 2017, Frontiers in Neuroendocrinology.

[20]  T. R. Chang,et al.  The Mediation Model. , 2016 .

[21]  B. Aouizerate,et al.  Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset. , 2016, Schizophrenia bulletin.

[22]  Adham Mancini-Marı̈e,et al.  Sex/gender differences in the brain and cognition in schizophrenia , 2016, Neuroscience & Biobehavioral Reviews.

[23]  A. Maggi,et al.  Estrogens, Neuroinflammation, and Neurodegeneration. , 2016, Endocrine reviews.

[24]  V. Steen,et al.  The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis , 2016, BMC Psychiatry.

[25]  April Au,et al.  Estrogens, inflammation and cognition , 2016, Frontiers in Neuroendocrinology.

[26]  R. Kuwano,et al.  Elevated C-Reactive Protein Is Associated with Cognitive Decline in Outpatients of a General Hospital: The Project in Sado for Total Health (PROST) , 2016, Dementia and Geriatric Cognitive Disorders Extra.

[27]  C. Depp,et al.  Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups , 2015, Schizophrenia Research.

[28]  P. McKenna,et al.  Validation of the Spanish version of the Clinical Assessment for Negative Symptoms (CAINS) , 2015, Schizophrenia Research.

[29]  M. Berk,et al.  C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications , 2015, Molecular Psychiatry.

[30]  B. Wyble,et al.  Temporal perception deficits in schizophrenia: integration is the problem, not deployment of attentions , 2015, Scientific Reports.

[31]  Peter B. Jones,et al.  Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. , 2015, The lancet. Psychiatry.

[32]  R. Heaton,et al.  The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in China , 2012, Schizophrenia Research.

[33]  F. Dickerson,et al.  Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. , 2013, Journal of affective disorders.

[34]  K. Nuechterlein,et al.  The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in Spain , 2012, Schizophrenia Research.

[35]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[36]  D. Strachan,et al.  Sex differences in the relationship between inflammatory and hemostatic biomarkers and metabolic syndrome: British 1958 Birth Cohort , 2011, Journal of thrombosis and haemostasis : JTH.

[37]  J. Goldstein,et al.  Sex differences in schizophrenia , 2010, International review of psychiatry.

[38]  C. Hermenegildo,et al.  Menopause and Ovariectomy Cause a Low Grade of Systemic Inflammation that May Be Prevented by Chronic Treatment with Low Doses of Estrogen or Losartan1 , 2009, The Journal of Immunology.

[39]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[40]  L. San,et al.  Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia , 2004, Schizophrenia Research.

[41]  V. Peralta,et al.  Psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia , 1994, Psychiatry Research.